StemCells, Inc.
 | hideThis article has multiple issues. Please help or discuss these issues on the . (Learn how and when to remove these template messages)
|
 | |
| Type | Public |
|---|---|
| Industry | Biotechnology |
| Headquarters | , United States  |
Key people | Ian Massey (CEO) Irving L. Weissman, M.D. (Founder) |
| Website | www.stemcellsinc.com |
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.[1][2]
They are being studied in early stage trials.[3][4]
On November 28, 2016, StemCells merged with Microbot Medical Ltd. and became Microbot Medical Inc.
In March 2020, Microbot Medical Inc. announced the appointment of Eyal Morag, M.D. to Chief Medical Officer.[5]
References[]
- ^ Falco, Miriam. (Sept. 7, 2012). "A tiny step forward for spinal cord injuries."
- ^ Le Roux, Mariette. (March 5, 2014). "Science sees future beyond Paralympics."
- ^ http://www.clinicaltrials.gov/ct2/show/NCT02163876
- ^ "StemCells Inc says spinal injury therapy shows promise". Reuters. 2015-11-18. Retrieved 2015-12-23.
- ^ "Microbot Medical Appoints Eyal Morag M.D. as Chief Medical Officer". BioSpace. Retrieved 2020-03-03.
External links[]
| Authority control |
|
|---|
Categories:
- Biotechnology companies of the United States